Trial · NCT03435640
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | 0 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | 0 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | 0 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | 0 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | 0 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | 0 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | 0 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | 0 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | 1 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | 0 | Participants | ||
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | 0 | Participants | ||
| Objective Response Rate (ORR) Per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | 0 | 95% Confidence Interval 0.0 to 23.2 | percentage of participants | |
| Objective Response Rate (ORR) Per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | 14.3 | 95% Confidence Interval 1.8 to 42.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03435640/results